

Q3 2022 Results

17 November 2022

CHRISTER NORDSTEDT MD PhD, ACTING CEO
ROBERT MAIORANA, ACTING CFO



Forward-looking statement

Important notice

The information in this presentation shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in any jurisdiction in which such offer, solicitation or sale would require preparation of further prospectuses or other offer documentation, or be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction.

No representation or warranty expressed or implied is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinion contained herein.

The information in this presentation may not be forwarded or distributed to any other person and may not be reproduced in any manner whatsoever. Any forwarding, distribution, reproduction, or disclosure of this information in whole or in part is unauthorized. Failure to comply with this directive may result in a violation of the Securities Act or the applicable laws of other jurisdictions.

Forward looking statements

This presentation contains forward-looking statements that reflect management's current views with respect to certain future events and potential financial performance. Although Vivesto believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct. Accordingly, results could differ materially from those set out in the forward-looking statements as a result of various factors.

Important factors that may cause such a difference for Vivesto include but are not limited to: (i) the macroeconomic development, (ii) change in the competitive climate and (iii) change in interest rate level.

This presentation does not imply that Vivesto has undertaken to revise these forward-looking statements, beyond what is required by applicable law or applicable stock exchange regulations if and when circumstances arise that will lead to changes compared to the date when these statements were provided.

Today's speakers



CHRISTER NORDSTEDT MD PhD
Acting Chief Executive Officer



ROBERT MAIORANA
Acting Chief Financial Officer

Q3 results – operational updates

- Christer Nordstedt MD PhD was appointed acting CEO
- Vivesto winds down activities in Russia
- Vivesto noted the launch of Apealea[®] in Germany by Inceptua

Post period end

- Christer Nordstedt resigned as acting CEO
- Nina Herne PhD MBA brought in to spear head our Business Development

Positioning Vivesto for the next stage of its growth...



Building our capabilities to attract innovative assets

Accelerating Business Development and in-licensing

Securing our financial position well capitalised with no debt

Reducing business risks and operating expenditure

New leadership Chairman in place; CEO & CFO being recruited

Apealea[®] launches and driving our clinical pipeline

Review of Vivesto's assets and projects



Three main focus areas

Review of Vivesto's assets and projects

to further
**strengthen
the research
portfolio**

to increase
the value of
**existing
projects and
technology
platforms**

**to further
trim our
costs** to be
able to invest
in value
creation
through R&D



Existing business

Oncology R&D

in-licensed & wholly-owned development-stage assets

- Cantrixil
- Docetaxel micellar
- Strategic pipeline development (string of pearls)



Commercial

revenues from out-licensed products and technologies

- Apealea® for ovarian cancer
- XR-17™ / XR-18 drug delivery technologies
- Animal health assets for partnering or continued development



Aiming to build critical mass in cancer


Significantly broadened pipeline by implementing 'string of pearls' strategy

Product	Indication	Pre-clinical	Phase 1	Phase 2	Phase 3	Registration / approval	Commercial Launch	Geography	
Apealea® (paclitaxel micellar)	Ovarian cancer	→							EU/EEA
Apealea® (paclitaxel micellar)	Ovarian cancer	→						US	
Cantrixil IP	Ovarian cancer	→						Global	
Docetaxel micellar	Prostate cancer	→						EU/EAA	
Cantrixil New Formulation	Ovarian cancer	→						Global	



Docetaxel micellar – Phase Ib in advanced prostate cancer on track

- SAKK open-label, multi-center, single-stage trial at three Swiss hospitals
- Targeting 18 chemotherapy-naive patients with **metastatic castration-resistant prostate cancer (mCRPC)**
 - First patient fully completed study (Feb 2022)
 - About half of the patients are recruited
 - Recruitment is expected to be completed in H1 2023
 - Further sites may be added to accelerate recruitment



XR-17™/XR-18 – progress on next generation development

Solubilization platform expansion & enhancement


- Promising novel candidate for use with XR-18 identified and synthesized
- Testing underway with widely-used oncology compound
- Potential for improved properties and capabilities vs. XR-17™
- Agreement with Visikol Inc. to evaluate cellular effects & enable selection of promising oncology candidates

Apealea[®] – European launches underway



- Launched in Germany by Inceptua 15 August 2022
- UK commercialisation plans progressing
 - Inceptua, has secured a maximum list price for Apealea[®] with the Department of Health and Social Care, allowing private market access
 - Inceptua is engaged with NHS England to secure reimbursement
- Other European launches will be implemented on a country-by-country basis over the next couple of years
- First royalties for Vivesto are anticipated in 2023

- Germany – launched
- UK – commercialisation plans progressing




Q3 financials – a solid cash position, no debt and operating costs reduced

- Improved cashflow from operating activities MSEK -22.6 (MSEK -25.3)
- Operating loss totalled MSEK -71.3 (MSEK -29.6)
- Write-down of development costs attributable to Russia MSEK -44.6 (0)
- Operating loss Q3 adjusted for write-down of development costs attributable to Russia MSEK -26.7 (-29.6), a decrease of MSEK 2.9.
- Operating loss YTD adjusted for write-down of development costs attributable to Russia MSEK -89.3 (-126.6), a decrease of MSEK 37.2
- Short-term investments and cash and cash equivalents amounted to MSEK 164.2 (MSEK 149.7).
- A solid financial position with an equity/asset ratio of 95% and no debt

Thank you

Vivesto AB (STO: VIVE)
Vallongatan 1
752 28 Uppsala
Sweden

 +46 018-50 54 40

 IR@vivesto.com

 www.vivesto.com

 www.linkedin.com/company/vivesto-ab

 www.twitter.com/vivesto

